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Abstract
Background Regions within England, Scotland and Wales show variation in rate of adoption of biosimilar infliximab and 
etanercept.
Objectives This study aims to examine how local decisions and practices in regions within England, Scotland and Wales 
might explain initial variation in market dynamics of biosimilar and originator infliximab and etanercept.
Methods Market data provided by the National Health Service (NHS) on biosimilar and originator infliximab and etanercept 
uptake were analysed for the 10 historical regions of England, 14 health boards in Scotland and 7 health boards in Wales 
(2015–2018). Findings were discussed in ten semi-structured interviews: on a national level with an industry representative 
(1), on a regional level with NHS employees in England (6), Scotland (1) and Wales (1), and on a local level with a repre-
sentative of a clinical commissioning group in England (1).
Results Tenders for infliximab and etanercept in England, Scotland and Wales have consistently resulted in a biosimilar 
as the best value biological. Early and late biosimilar adopters are seen, with overall convergence towards high biosimilar 
market shares over time. Qualitative results suggest that biosimilar adoption was positively influenced by (a) a price differ-
ence between biosimilar and originator product making it worthwhile to switch patients; (b) a good relationship between 
commissioner and provider in England resulting in gain share agreements; (c) leadership on biosimilars in regional NHS 
offices in England or Scottish and Welsh health boards; (d) key opinion leaders or leading hospitals that start using biosimi-
lars early and gain experience.
Conclusions This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good 
stakeholder relationships, and clinician engagement were identified as early adopters.
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Key Points 
Considerable variation in the rate of adoption of inf-
liximab and etanercept biosimilars is observed within 
England, Scotland and Wales.
Implementation of biosimilars into clinical practice is 
facilitated by gain share agreements, regional and local 
leadership, and sharing of best practices from early adop-
ters.
Over time, there is convergence towards high biosimilar 
market shares across England, Scotland and Wales.
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1 Introduction
The loss of exclusivity of blockbuster tumour necrosis fac-
tor (TNF)-α inhibitors in 2015  (Remicade®: infliximab; 
 Enbrel®: etanercept), and 2018  (Humira®: adalimumab) 
triggered the entry of biosimilars for these molecules into 
the European market. Biosimilar infliximab was the first 
biosimilar monoclonal antibody to receive a positive opin-
ion from the European Medicines Agency (EMA), followed 
by marketing authorization for the European Union under 
the names  Inflectra® and  Remsima® [1]. Later, infliximab 
biosimilars  Flixabi® and  Zessly®, etanercept biosimi-
lars  Benepali® and  Erelzi®, and adalimumab biosimilars 
 Amgevita®,  Imraldi®,  Hyrimoz®/Hefiya®/Halimatoz®, 
 Hulio®,  Idacio® and  Amsparity® were authorized. A full 
list of authorized biosimilars and marketing authorization 
dates can be consulted on the website of the EMA [1].
As spending on infliximab, etanercept and adalimumab 
for the National Health Service (NHS) in England totalled 
£545 million of the £16.8 billion that was spent on medicines 
in the year 2015–2016 [2], competition from biosimilars 
could induce considerable savings. Uptake of biosimilars 
varies widely both across Europe [3] and within individual 
countries [4–9], due to variation in implemented pricing 
and reimbursement procedures and demand-side measures 
supporting the use of biosimilars [10]. A study by Alnahar 
et al. [6] indicated in 2017 that uptake of the first wave of 
biosimilars (i.e. somatropin, epoetin and filgrastim) varies 
geographically across Great Britain (England, Scotland and 
Wales), and warrants further investigation of the reasons for 
variability of biosimilar uptake. Two years after the entry of 
infliximab biosimilars in England, uptake still varied from 
below 10% biosimilar usage up to 99% across Acute Trusts 
(i.e. Hospital Trusts, accountable organisations within NHS 
England that manage and control the performance, services 
quality and financial efficiency of clusters of hospitals in 
England) [2]. Savings for infliximab and etanercept for the 
year 2017–2018 already totalled £166 million [11], but 
more could be achieved when fully leveraging biosimilar 
competition.
The aim of this study was to determine the influence of 
local decision making and practices on early biosimilar inf-
liximab and etanercept adoption in subregions of England, 
Scotland and Wales. This builds further on our previous 
work investigating regional variation in uptake of biosimilar 
infliximab and etanercept in the 21 counties of Sweden [4, 
5]. This similar study in Sweden has shown that the main 
driver for biosimilar use is the extent of the actual price dif-
ference, after discounts and rebates, between biosimilar and 
originator product. Additionally, the attitude of key opinion 
leaders, local guidelines and gain sharing influenced bio-
similar/originator market dynamics. Enabling factors such as 
a multi-stakeholder approach, an altruistic attitude and good 
communication were also identified. In the present study on 
biosimilar adoption in subregions of England, Scotland and 
Wales, we want to validate these findings and study whether 
the drivers for biosimilar adoption in Sweden are also valid 
in other healthcare systems. In addition, approaches for the 
adoption of adalimumab biosimilars will be commented on 
in the discussion section of this paper, as a full analysis was 
not possible given their recent entry at the time of the study.
2  Methods
This study is a mixed methods study based on an exploratory 
literature review, a quantitative part including analysis of 
biosimilar uptake trends, and a qualitative part with semi-
structured interviews.
An exploratory literature review was conducted in Pub-
Med, combining search terms on biosimilars, the United 
Kingdom (UK), Great Britain, England, Scotland and Wales. 
In addition, a Google search was performed to include grey 
literature, such as websites and documents on biosimilars 
from the NHS in England, Scotland and Wales.
With a view to describing regional biosimilar uptake 
trends over time, biosimilar infliximab and etanercept mar-
ket shares over time are presented for the ten historical sub-
regions of England, fourteen health boards in Scotland and 
seven health boards in Wales (2015–2018). These market 
shares were calculated as volume of biosimilars over vol-
ume of biosimilars plus originator product, with volumes in 
defined daily doses (DDDs) in the case of England and Scot-
land, and in vials for Wales. As defined by the World Health 
Organization, a DDD of infliximab or etanercept is a unit 
that is expressed as the average daily maintenance dose for 
their main indication in adults, namely rheumatoid arthritis 
[12, 13]. Although the use of vials provides a more unam-
biguous view on the use of infliximab as only one strength 
is available (i.e. 100-mg vials), the calculation of a ratio 
to present market shares will render the same results when 
expressed in vials or DDDs. For etanercept, the use of DDDs 
is preferred to take into account different presentations. As 
the etanercept data for Wales are based on vials instead of 
DDDs, we would expect small discrepancies. Market data 
on biosimilar and originator infliximab and etanercept 
were provided by the NHS in England, Scotland and Wales 
through personal communication in the case of England and 
Wales, and via an information request for Scotland (HMUD 
and PRISMS databases [14]; please note that hospital drug 
utilisation does not necessarily equate to drug consumption). 
The ten-region level in England aligns with the former Stra-
tegic Health Authority areas as formed in 2006 after a reor-
ganisation [15, 16], and was chosen since communication 
still occurs at this level (although abolished in 2013). In 
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Wales, changes were introduced in April 2019 with respect 
to the names and covered population of the health boards 
[17]. Names of the health boards used throughout the text 
and figures still reflect the situation before 1 April 2019. 
Early and late adopters are discussed by visually examining 
biosimilar uptake trends over time for the different regions. 
A more extensive (statistical) analysis was not possible given 
that the factors that seemed to influence biosimilar uptake 
are hard to quantify and the available data points (regions) 
are limited. Furthermore, we did not have access to actual 
prices, including discounts following tender procedures.
Ten semi-structured interviews (i.e. interviews that are 
conversational in tone, but guided by an interview guide 
[18]) were conducted in order to gain insight into which 
factors determined early and late adoption of biosimilars in 
the ten historical regions in England, fourteen health boards 
in Scotland and seven health boards in Wales. The focus 
of the study was initially on England, with its ten histori-
cal regions, and we later expanded to investigate whether 
the same drivers and enablers were found for Scotland and 
Wales. First, an overarching interview was conducted with 
an industry representative to ask questions on the healthcare 
system in the UK, in addition to questions related to the bio-
similars market. Then, six interviews were conducted with 
NHS England employees in NHS North East, NHS North 
West, NHS Yorkshire and the Humber, NHS East of Eng-
land, NHS West Midlands, and NHS South East Coast. Via 
these six interviews, information was also obtained on the 
four remaining regions (East Midlands, London, South West 
and South Central) for which no specific interview was car-
ried out. One interview with a representative of a clinical 
commissioning group (an organisation that pays for health-
care services and medicines) in England was conducted to 
explore whether the obtained information on a regional level 
corresponds with factors that are perceived to influence bio-
similar adoption on a local level. Finally, in order to broaden 
the scope of the study, two interviews were conducted with 
representatives from NHS Scotland and NHS Wales.
Interviewees were contacted via email for their participa-
tion. Once confirmed, an informed consent form was shared 
to ask for permission to record the interview for transcrip-
tion purposes. The interviews were conducted via telephone, 
based on an interview guide to structure the interview, and 
were later transcribed verbatim, pseudonymised and ana-
lysed in a qualitative way. A framework approach, which is 
often adopted in applied qualitative research, was used to 
analyse the data [19]. First the transcripts and notes taken 
during the interview were read to familiarize with the data, 
then a thematic framework was constructed based on topics 
in the interview guide (national, regional and local meas-
ures for different stakeholders) and issues emerging from 
the interviews; subsequently the framework was applied and 
the data were rearranged and interpreted [20]. Questions 
were related to policies and practices in a region, especially 
with regard to infliximab and etanercept biosimilars, and 
how they would explain regional variation and faster/slower 
biosimilar adoption in other regions. All interviews were 
carried out in English between September 2018 and Febru-
ary 2019. As the interviews served to gather information 
on policies and local practices, there might be overlap with 
results from the literature review. Furthermore, interviewees 
pointed out additional websites and documents, which are 
referred to where relevant.
Findings from this mixed methods study are reported in 
an integrated way, with references to the literature to cor-
roborate interview results, and quantitative results further 
explained by learnings from the interviews. Some of our 
results might not be specific for just the biosimilar infliximab 
and etanercept market, since implemented policy measures 
might have a broader scope. In addition, some barriers and 
facilitators for biosimilar adoption might not be product spe-
cific. However, this can only improve the generalizability of 
the study results to other biosimilar products.
3  Results
Integrated results of the literature review, data analysis and 
interviews are discussed separately for England, Scotland 
and Wales. However, we observed some common charac-
teristics for these countries with regards to the infliximab 
and etanercept market, that is, both molecules are procured 
by tendering and prescribed by brand name by specialists 
in the hospital, infliximab is administered in the hospital 
and etanercept mainly via homecare services, biosimilars 
for infliximab and etanercept have been the best value offer 
in tender procedures in England, Scotland and Wales. It was 
reported during the interviews that clinicians’ confidence is 
growing with hands-on experience and more evidence about 
the efficacy and safety of biosimilars and switching from 
the originator to the biosimilar. In addition, pharmacists 
and other healthcare professionals, such as nurses, support 
the switch process. When correctly framed and consider-
ing shared decision making, patients have also accepted 
a switch to a biosimilar. A major difference between the 
healthcare system in England versus Scotland and Wales 
is the commissioner-provider split in England, where you 
have clinical commissioning groups (CCGs) on the demand 
side and hospital trusts on the supply side [21]. In addition, 
tender prices can differ between regions in England, while 
there is only one national price in Scotland and Wales [2].
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3.1  England
3.1.1  General Observations of the Biosimilars Market
In England, the provision of healthcare and integration of 
national policy measures on a local level is governed by 
the different CCGs and Trusts, with overarching regional 
structures to align implementation, such as the former ten 
Strategic Health Authorities at which level communication 
related to biosimilars still occurs. In addition to the work of 
the CCGs, specialised care such as medicines for the treat-
ment of cancer is commissioned by NHS England itself. This 
is the case for originator and biosimilar trastuzumab, and 
for the oncology indications for originator and biosimilar 
rituximab, while this is the responsibility of the CCGs for 
infliximab and etanercept.
Several national position statements and recommenda-
tions on the use of biosimilars are in place. A non-exhaustive 
overview is provided in Table 1. In general, the biosimi-
lar market in England is characterized by a high focus on 
education and open discussion; for example, via national 
initiatives as outlined in Table 1, regional workshops, and 
documents on the website of the NHS Specialist Pharmacy 
Service, including a toolkit for the adoption of biosimi-
lar adalimumab [22]. In addition, uptake of biosimilars is 
closely monitored and matched with appropriate activities 
to improve their use.
Competitive pricing for infliximab and etanercept occurs 
via a special tender procedure. First, a national tender is 
set up resulting in a framework agreement with usually a 
number of manufacturers in order to determine prices on a 
national level. Then, a 2-year rotational tendering system 
starts in the four regions (London, North, South, and Mid-
lands and East of England), with a new tender starting in 
a different region every 6 months. This gives the oppor-
tunity for companies to compete in multiple tenders and 
still provides a large volume to the winner. However, even 
though tendering occurs on a four-region level, decisions 
still tend to be taken on a ten-region level as this facilitates 
communication.
3.1.2  Regional Approaches Towards the Entry of Infliximab 
and Etanercept Biosimilars
3.1.2.1 Infliximab Although all regions should follow 
national policy, differences exist in how well this is imple-
Table 1  A non-exhaustive overview of policy measures and recommendations related to biosimilars in England
Year Details
2015 and 2019 In September 2015, NHS England published an information guide (‘What is a biosimilar medicine?’) with the aim to educate 
stakeholders on the role of biosimilars [51]. This guide was created in collaboration with industry and pharmacists’ associa-
tions, and regulatory and health technology assessment (HTA) authorities. An update was published in May 2019, also involv-
ing a patient organisation for rheumatoid arthritis patients and clinicians (via the Biosimilars Programme Board) [52].
2015–2018 The National Institute for Health and Care Excellence (NICE), England’s HTA body, had updated already in 2015 its guidelines 
for evaluation of biosimilars [53]. In addition, from 2016 to 2018, NICE provided updates on the information and evidence 
available for adoption of biosimilars within NHS England [54], and has published specific medicines evidence commentaries 
on, for example, bioequivalence between biosimilar and reference TNF-α inhibitors in 2017 [55].
2017 In September 2017, NHS England published its Commissioning framework for biological medicines (including biosimilars 
medicines), which urges commissioners to leverage competition from biosimilars via a collaborative approach and sets out 
a target of at least 90% of new patients on the best value biological medicine within 3 months after the entry of a biosimilar 
[2]. When choosing a best value biological medicine, which can be either the biosimilar or the originator depending on the 
offer, an evaluation needs to be carried out of “transparently costed device training, any patient support programs offered by 
manufacturers, administration costs, dosage and price per dose” [2]. Furthermore, at least 80% of existing patients should 
be switched to the best value biological product within 12 months after the entry of the biosimilar. When this target is not 
reached, commissioners will have to provide justification. For hospitals, these targets are linked to a financial incentive 
through a Commissioning for Quality and Innovation (CQUIN) scheme [56].
2017 To ensure local implementation, biosimilars have been taken up by the Regional Medicines Optimisation Committees 
(RMOCs). Four RMOCs that cover London, the South, the North, and the Midlands and East of England started in 2017 tar-
geted with reducing variation in the optimal use of medicines between regions and aligning local implementation of national 
policy measures [57]. Regional procurement pharmacists try to align national and regional policy and facilitate implementa-
tion by, for example, highlighting to trusts what the potential savings are and producing reports to demonstrate this.
2017 In 2017, the Cancer Vanguard, a part of the NHS established to follow up their National Cancer Strategy [58], developed in col-
laboration with Sandoz an interactive document with a proposed biosimilar adoption process timeline, including educational 
and supporting material for switching patients. The timeline flowchart initially aimed to facilitate the introduction of rituximab 
biosimilars in 2017, but is highly relevant for other therapeutic areas [59].
2018 In 2018, with the upcoming loss of exclusivity of originator adalimumab in mind, a national biosimilars programme board was 
created, consisting of hospital clinicians, pharmacists, procurement pharmacists, nurses, patient associations, authorities and 
industry (both biosimilar and originator), and is chaired by NHS England’s Chief Pharmaceutical Officer. This board aims to 
drive biosimilar use by advising NHS England.
79Characteristics of Early and Late Adopters of Biosimilars in England, Scotland and Wales
mented within each region. Figure 1 shows biosimilar inflix-
imab market shares over time for the ten historical regions 
of England. Exclusivity rights on infliximab expired on 
February 24, 2015 in the UK, and first sales for infliximab 
biosimilars can be observed in March 2015. One year after 
the entry of biosimilar infliximab, market shares still varied 
from 15 to 83%. Two years later, this variation was reduced 
to 63–91%. However, it took up to August 2018, three and 
a half years later, for all regions to reach market shares of at 
least 90%. Quick and slow adopters can be observed in each 
of the four tender regions.
Upon visual examination, two early adopters can be 
clearly distinguished, NHS South Central (light orange line) 
and NHS South West (dark orange line), with two distinctive 
approaches to increase biosimilar infliximab market shares 
(clinician versus payer initiated, respectively). In the South 
Central region, Southampton General Hospital introduced 
a managed switching programme for inflammatory bowel 
disease (IBD) patients on infliximab in April 2015, led by 
Dr Fraser Cummings [23]. The existing good relationship 
between the hospital and local CCGs was used to arrange a 
50:50 gain share agreement on cost savings, on top of agreed 
investments in staffing at the IBD department. Neighbour-
ing hospitals in the South Central region also became early 
adopters. A second early adopter, the South West region, had 
one large CCG that introduced a capped medicines budget 
for hospitals, which forced the adoption of biosimilars in 
order not to exceed the budget. Trusts that were not in this 
CCG learned from the early experience with biosimilars of 
other hospitals and also became early adopters.
NHS Yorkshire and the Humber (red line) was initially 
a slow adopter of biosimilar infliximab, as they were con-
cerned that the price of originator infliximab would go up 
when the volume decreased and did not want to take this 
risk, while other regions with the same procurement con-
tract had a different interpretation. Once this was clarified, 
adoption of biosimilar infliximab quickly increased, aided by 
multi-stakeholder overarching regional committees that were 
proven effective in other clinical areas and focused on educa-
tion of stakeholders, sharing of contract award information 
and follow up of uptake and local barriers. Collaboration 
between commissioners and providers led to gain share 
agreements for most trusts. A region that was lagging until 
3 years after the entry of infliximab biosimilars is the West 
Midlands (dark green line), where this joined-up approach 
is lacking, and less interaction exists between CCGs and 
trusts. Also for other regions, negotiations on gain share 
agreements initially delayed uptake of biosimilar infliximab, 
with trusts without an agreement lacking resources to switch 
patients to the biosimilar. Some CCGs decided to initially 
only start new patients on the biosimilar to increase trust of 
clinicians in biosimilars, and in a later stage implement a 
switching process supported by financial resources.
3.1.2.2 Etanercept In Fig. 2, biosimilar etanercept market 
shares over time are presented for the ten historical regions 
in England. The first etanercept biosimilar received market-
ing authorization for use in the European Union in Janu-
ary 2016. First sales can be observed in March 2016 but 
are limited to one region (1% in the South West region). 
One year later, biosimilar etanercept market shares varied 
from 15 to 76%, and 2 years later from 54 to 87%. Visually 
examined, no distinctive early adopters can be identified for 
biosimilar etanercept. The South West, South Central and 
Yorkshire and the Humber regions are again quick adop-
ters, along with the London region, while the West Mid-
lands region lags behind again. Given the experience with 
biosimilar infliximab, the expectation would be that uptake 
of biosimilar etanercept is quicker. However, it was reported 
that the originator company tried to match the biosimilar 
price bid in the case of etanercept, resulting in a similar rate 
of uptake for biosimilar etanercept compared to biosimilar 
infliximab. A less clear financial benefit for the use of bio-
similar etanercept slowed the switch to the biosimilar and 
made some regions, such as the West Midlands region, ini-
tially decide to stay with the originator product. In addition, 
Fig. 1  Biosimilar infliximab 
market shares for the ten 
historical regions in England, 
calculated as volume (defined 
daily doses) of the biosimilars 
over volume of the biosimilars 
plus reference product, from 
2015 to 2018
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the training aspect for a different device is important and 
there is limited capacity available for this. Furthermore, it 
was mentioned that the homecare provision of etanercept 
offers patients more opportunity to discuss and potentially 
object to the switching process.
3.2  Scotland
In Scotland, there are 14 territorial health boards that are 
responsible for patient care in their area, covering both pri-
mary and secondary care services [24]. In addition to local 
decision making through the health boards, several national 
organisations exist that provide support and guidance on 
overall healthcare objectives, such as Healthcare Improve-
ment Scotland, which developed a national prescribing 
framework for biosimilars in 2015, in consultation with the 
health boards [25]. In order to take into account advancing 
experience with biosimilars, this framework was updated 
in 2018 and provides more detailed information on clinical 
adoption of biosimilars, including good practice case stud-
ies and a patient switch letter template [26, 27]. Recom-
mendations in this framework distinguish between new 
patients, who should be prescribed the most cost-effective 
biological, and existing patients, for whom a switch to a 
biosimilar should be considered when economically benefi-
cial. The latter includes an assessment of the cost of change 
and the price difference between the originator and biosimi-
lar product. The use of ‘invest to save’ arrangements (e.g. 
recruitment of additional staffing) is advised to help hospi-
tals overcome the hurdle of switching patients. However, 
no formal gain share agreements exist with hospitals and 
all savings thus stay within the health board. Since the year 
2018–2019, biosimilars are included as a secondary care 
National Therapeutic Indicator and uptake of biosimilar 
infliximab, etanercept and rituximab in the different health 
boards is published [28].
Given the national framework for tendering (unranked 
multi-supplier), the same prices apply throughout the coun-
try and do not contribute to regional variations. Imple-
mentation of policy measures and guidance for adherence 
to national policies is up to the 14 health boards, and this 
gives rise to considerable variation in uptake of biosimilar 
infliximab and etanercept (see Figs. 3 and 4). First sales for 
biosimilar infliximab can be observed only in April 2016 
in Scotland. One year later, biosimilar infliximab market 
shares varied from 0 to 100%. When excluding smaller 
Fig. 2  Biosimilar etanercept 
market shares for the ten 
historical regions in England, 
calculated as volume (defined 
daily doses) of the biosimilars 
over volume of the biosimilars 
plus reference product, from 
2016 to 2018
Fig. 3  Biosimilar infliximab 
market shares for the 14 health 
boards in Scotland, calculated 
as volume (defined daily doses) 
of the biosimilars over volume 
of the biosimilars plus reference 
product, from 2016 to 2018
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health boards covering the islands of Scotland (Orkney, 
Shetland and Western Isles), this variation is reduced to 
17–100%, with only one health board having biosimilar inf-
liximab market shares below 80%. Two years after the entry 
of biosimilar infliximab, in April 2018, all health boards had 
biosimilar infliximab market shares between 90 and 100%. 
For biosimilar etanercept, first sales can be observed in May 
2016, followed by large variations in uptake of biosimilar 
etanercept between the different health boards. At the end 
of 2018, this variation was limited to 79–94% (excluding 
regions with low use of etanercept, i.e. Borders, Orkney, 
Shetland and Western Isles). The slower uptake of biosimilar 
etanercept compared with biosimilar infliximab was attrib-
uted to a training aspect to make patients comfortable to use 
a new device for subcutaneous administration. This is further 
complicated by the use of homecare services for etanercept, 
versus a quick switch of an infusion of infliximab in the 
hospital setting. 
Some health boards were quicker than others to adopt bio-
similar infliximab and etanercept. At NHS Highland (dark 
brown line), the gastroenterology team decided to start IBD 
patients on biosimilar infliximab and switch existing patients 
from originator infliximab to a biosimilar as soon as the 
biosimilar became available (April 2016), in order to keep 
their budget under control [27]. They developed a switch 
letter to inform existing patients prior to their next appoint-
ment and offered the opportunity to discuss any questions 
they may have to make an informed decision. These switch 
letters were adopted on a national level in March 2016 for 
infliximab as well as etanercept and have been adapted by 
other health boards [26, 27]. Figure 3 shows that efforts from 
NHS Highland paid off, with a biosimilar infliximab market 
share of 85% in the first month. Many other health boards 
also made a quick start, with primarily smaller health boards 
lagging behind. Learnings from the gastroenterology team in 
NHS Highland were shared with the rheumatology team in 
order to successfully switch etanercept patients. However, as 
can be seen in Fig. 4, this took some time and compared with 
other health boards, they were late adopters. Results from 
a switch programme for rheumatology patients on etaner-
cept in the NHS Grampian Health Board (orange line) that 
started in August 2016 [27] also experienced a lag of several 
months. Patients on etanercept normally have consultations 
scheduled only every 6 months. A mixed model was used to 
call back some patients earlier to make a switch to biosimilar 
etanercept.
Additional factors that were mentioned during the inter-
view that might explain variation in biosimilar uptake 
between health boards were the presence of a project man-
ager or clinical leader within the health board that drives 
the switch, and investments of some health boards in addi-
tional staffing to support the switch process. The latter was 
especially helpful for the switch to biosimilar etanercept, 
where additional consultations needed to be scheduled when 
proactively switching, and the change to a different device 
required training.
3.3  Wales
Within Wales, the seven autonomous health boards are 
responsible for health policies and guidance, for both pri-
mary and secondary care in their region. A national policy 
framework for biosimilars emphasises that biosimilars are a 
priority for NHS Wales and provides direction for all health 
boards. As of April 2016, prescribing of biosimilars has been 
an All Wales Medicines Strategy Group (AWMSG) National 
Prescribing Indicator (NPI). This indicator is to support cost-
effective prescribing of selected biological medicines where 
biosimilar versions are available [29], therefore supporting 
the appropriate use of best value biologicals. Quarterly mon-
itoring reports for NPIs, including on uptake of biosimilars 
versus their reference product, are published online by the 
Welsh Analytical Prescribing Support Unit (WAPSU), which 
is part of the All Wales Therapeutics and Toxicology Centre 
(AWTTC) [30]. These data show variation between the dif-
ferent health boards. In order to reduce variation and support 
Fig. 4  Biosimilar etanercept 
market shares for the 14 health 
boards in Scotland, calculated 
as volume (defined daily doses) 
of the biosimilars over volume 
of the biosimilars plus reference 
product, from 2016 to 2018
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health boards to increase uptake of biosimilars, a variety of 
activities were undertaken. In 2017, biosimilars were part of 
a Best Practice Day, where experience in rheumatology from 
early adopter, Aneurin Bevan University Health Board, was 
shared with other health boards [31]. At the start of 2019, 
a dedicated multidisciplinary Biosimilar Best Practice Day 
was organised, with the aim to increase biosimilar uptake 
and reduce variation between health boards [32].
Challenges that have been raised concerning switching 
patients to the most cost-effective biosimilar are mainly 
related to a lack of capacity to have a conversation with 
existing patients on the reference product, leading to an ini-
tial delay in uptake of biosimilars. It is recommended that 
patients are involved in the decision making and give their 
consent before being switched to a biosimilar. Figures 5 and 
6 show biosimilar infliximab and etanercept market shares 
for the individual health boards. First sales of biosimilar 
infliximab can be observed in quarter two of 2015. One year 
after the entry of biosimilar infliximab, market shares still 
varied from 12 to 83%, and after 2 years from 38 to 92%. 
At the end of 2018, this variation was reduced to 92–99%. 
First sales of biosimilar etanercept can be seen in quarter two 
of 2016, although only for one health board. One year after 
the entry of biosimilar etanercept, this variation still ranged 
from 0 to 81%. After 2 years, 54 to 98% and at the end of 
2018, this variation was only 73–98%. For etanercept, three 
early and three late adopters can be clearly distinguished 
when examining Fig. 6. 
The Aneurin Bevan University Health Board (dark blue 
line) can be clearly distinguished as an early adopter of both 
biosimilar infliximab and etanercept. In November 2015, a 
position statement on biosimilars was issued by the health 
board and signed by a rheumatologist who serves on the 
health board [33]. In June of 2017, this rheumatologist also 
shared experiences from the health board with biosimilars 
on the national Best Practice Day [31]. The Abertawe Bro 
Morgannwg University Health Board published its biosimi-
lar strategy in January 2018, mentioning approved actions to 
increase biosimilar uptake from January 2017 [34].
During the interview, some additional factors were put 
forward that might explain differences in biosimilar uptake 
between health boards. Variation could be due to differ-
ences in the initial experience levels of clinicians attained 
from both in-practice, and wider factors such as conference 
attendance where information on the switching of biosimi-
lars was presented.
Fig. 5  Biosimilar infliximab 
market shares for the seven 
health boards in Wales, calcu-
lated as volume (vials) of the 
biosimilars over volume of the 
biosimilars plus reference prod-
uct, from quarter two of 2015 to 
end of 2018. The seventh health 
board, Powys Teaching Health 
Board, is not shown, as this 
health board has no secondary 
care services
Fig. 6  Biosimilar etanercept 
market shares for the seven 
health boards in Wales, calcu-
lated as volume (vials) of the 
biosimilars over volume of the 
biosimilars plus reference prod-
uct, from quarter two of 2016 to 
end of 2018. The seventh health 
board, Powys Teaching Health 
Board, is not shown, as this 
health board has no secondary 
care services
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3.4  Factors Influencing Biosimilar Adoption
The identified factors that seem to positively influence bio-
similar uptake in the studied regions are summarized in 
Table 2. The overall key driver for regions to adopt biosimi-
lars are the cost savings that can be realized by moving to a 
lower-priced product. Although tendered prices might vary 
between the four regions in England (London, North, South, 
and Midlands and East of England) due to the regional rota-
tion system, potential differences in regional prices do not 
seem to influence uptake. As hospitals acknowledged a lack 
of resources available to manage the switching process, the 
negotiation of a gain share agreement, where part of these 
savings is shared with the hospitals, led to considerable 
improvements in biosimilar uptake. Investments in addi-
tional staffing to support the switching process also resulted 
in higher rates of biosimilar adoption. These negotiations 
were facilitated by relying on existing good relationships 
and networks. In addition, leadership within the organisa-
tions in a region and forerunners at the hospital will enhance 
biosimilar uptake. Colleagues with experiences of biosimi-
lar prescribing and switching of patients to a biosimilar are 
an important factor in changing prescribing behaviour of 
clinicians.
4  Discussion
The combination of a competitive pricing landscape where 
the biosimilar has been the least expensive treatment option 
and a strong focus on education and best practice sharing to 
eliminate initial scepticism and lack of understanding, have 
made the UK one of the European countries with the highest 
biosimilar market shares. This presents an interesting case 
study to illustrate how uptake has evolved over time and 
what drives biosimilar adoption. In this article, we describe 
regional-level decision making and practices related to the 
use of biosimilar infliximab and etanercept in the ten histori-
cal regions of England, 14 health boards in Scotland, and 
seven health boards in Wales, with a view to identify factors 
that characterize early and late adopters of these biosimilars 
and explain regional variation. This study adds to the scarce 
literature on factors influencing biosimilar adoption. Specifi-
cally for the UK, research has mainly focused on stakeholder 
perspectives on biosimilars and budget impact of biosimilars 
[35–41], while this article maps policies and local practices, 
and focusses on regional differences. A study by Alnahar 
et al. [6] already described geographical variability in uptake 
of biosimilars for somatropin, epoetin and filgrastim across 
Great Britain, but did not investigate local practices and fac-
tors influencing biosimilar adoption. Our findings align with 
results from a survey published in April 2018 from NHS 
England among CCGs and Trusts with the aim to identify 
barriers to biosimilar uptake and increase understanding 
of stakeholder positions [42, 43]. These reports highlight 
capacity problems to switch patients and a lack of clinician 
engagement as barriers to biosimilar adoption and found 
that gain share agreements and investment in additional staff 
are most often used as incentives to support a switch to a 
biosimilar.
Compared with results from our previous study on 
regional variation of biosimilar uptake in Sweden [4, 5], the 
lack of (staff) resources as a barrier to switch from the origi-
nator product to the biosimilar (and which needs to be over-
come via specific gain share agreements) was less apparent 
in Sweden, where hospitals felt that they receive the budget 
they need and a more altruistic attitude prevailed to adopt 
biosimilars with a view to generate savings for the healthcare 
system. It should be noted that the biosimilar is not always 
less expensive than the originator product in Sweden, which 
complicates a comparison of regional variation and speed of 
biosimilar uptake between the UK and Sweden. However, 
in general, the identified drivers for biosimilar uptake also 
seem to be consistent among other European countries such 
as Germany and Belgium [44, 45]; that is, the initial driver 
depends on the size of the net price difference between the 
biosimilar and originator product, then further incentives are 
needed for physicians; for example, local guidelines, pre-
scription targets and gain sharing. One should keep in mind 
that the ultimate goal is to introduce competition, leading to 
lowered treatment costs. In Sweden, a net price difference of 
40% between originator and biosimilar infliximab led to high 
biosimilar market shares [4]. In the case of etanercept in 
Sweden, the importance of demand-side policies was high-
lighted, with high biosimilar market shares with only limited 
net price differences between originator and biosimilar [5]. 
Adoption of biosimilars is enabled by a proactive attitude 
with multi-stakeholder engagement, and a good relationship 
Table 2  Identified factors in the qualitative analysis that positively influence regional-level uptake of biosimilar infliximab and etanercept in 
England, Wales and Scotland
Factors linked to high rate of biosimilar uptake (qualitative analysis)
A price differential between biosimilar and originator product (= potential cost savings)
Gain share agreements, aided by good relationships between commissioner and provider in England
Leadership on a regional/local level to implement national policy
Key opinion leaders in hospitals that gain early experience and motivate other clinicians
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and communication between decision makers and other 
stakeholders. A paper by Khan et al. voiced the lack of 
information on the impact of relationships between different 
stakeholders on uptake of new medicines, and acknowledges 
a ‘disconnect’ between policy makers who want to increase 
biosimilar uptake, adopters who carry the burden of change, 
and available information on how to implement the use of 
biosimilars in practice [46]. However, relationships are not 
easy to change and definitely do not change quickly.
In general, regional variations and rate of uptake of bio-
similar infliximab and etanercept by the regions seem to 
evolve in a similar way for England, Scotland and Wales. 
Uptake of biosimilar infliximab in Scotland can be observed 
to be quicker than in England and Wales, with most health 
boards having market shares above 80% after 1 year. How-
ever, it should be noted that the use of biosimilar infliximab 
in Scotland only started in April 2016, approximately 1 year 
later than in England and Wales. This probably influenced 
clinician engagement and preparedness to push a switch at 
the national and health board level. Furthermore, caution 
needs to be exercised when comparing biosimilar uptake 
patterns between England and Scotland/Wales because, for 
example, the regions are much larger in the former than in 
the latter. A higher uptake of biosimilar etanercept com-
pared with biosimilar infliximab due to evolving experience 
with biosimilars is not as apparent as we would expect, as 
a result of smaller price differences between biosimilar and 
originator etanercept, and a difference in treatment setting 
(i.e. homecare services).
While this article has focused on uptake of biosimilar 
infliximab and etanercept, we noticed that the entry of bio-
similars for the world’s best-selling medicine,  Humira® 
(adalimumab), at the end of 2018, has led to a revised strat-
egy to ensure their adoption and to generate corresponding 
cost savings. For England, this meant that efforts were more 
nationally coordinated to avoid missing the opportunity for 
savings from the start. In 2016, a dedicated adalimumab 
web page was created by the Specialist Pharmacy Service 
with briefing documents from RMOC meetings, educational 
material, resources to facilitate practical implementation 
(such as patient letter templates, an Excel file with different 
steps of implementation, and a tool to track cost savings), 
clinical information on each adalimumab product, and sta-
tus updates on the development of biosimilars going back 
as early as 2013 [47]. A new, national approach to tender-
ing was set up with multiple winners, where depending on 
the competitiveness of the bid, the company has access to 
a greater or smaller part of the market, which was divided 
into 11 regions [48]. Each region has access to the originator 
product as well as preferred biosimilars. Also in Scotland 
switching plans were discussed before loss of exclusivity 
rights on  Humira® and uptake statistics are shared monthly 
with health boards to benchmark their progress. One year 
after the introduction of adalimumab biosimilars in Europe, 
IQVIA reports biosimilar adalimumab market shares of 76% 
for the UK [49].
Several limitations can be attributed to this study. First, 
we did not conduct interviews for all regions in England 
and have only interviewed one person per region. However, 
information obtained during the interviews also covered 
regions for which no specific interview was carried out. In 
addition, questions mainly pertained to objective informa-
tion on how a region approached the adoption of biosimi-
lars, minimizing the need to conduct multiple interviews 
per region. Second, no local interviews were carried out 
with health boards in Scotland and Wales. However, these 
countries are far less populated than England, and one of 
the ten regions in England can cover as many people as the 
population in Scotland or Wales. Therefore, an alternative 
approach to ours could be to look at Scotland and Wales as 
additional regions on their own. Third, as it is difficult to 
quantify the influence of certain factors such as good rela-
tionships between stakeholders, we had to rely on qualita-
tive information obtained during the interviews and a few 
published position statements and case studies. Also, other 
factors than the ones we identified might potentially influ-
ence originator/biosimilar market dynamics. Nonetheless, 
the value of information from qualitative research should not 
be underestimated as this is often the only way to learn how 
policy measures affect stakeholder perceptions and behav-
iour, since information on local initiatives and implementa-
tion processes are often not published or quantifiable.
Future research should continue to investigate barriers 
and best practice case studies for the adoption of biosimi-
lars to generate learnings on originator/biosimilar market 
dynamics. Results of this study could be used as a start-
ing point to look at other therapeutic classes and molecules, 
including less complex biologicals (e.g. insulin, filgrastim). 
In particular, the case of late entrants for molecules with 
established biosimilars and how policy measures and local 
practices develop for possible biosimilar to biosimilar 
switching is as yet not well documented. With the entry of 
adalimumab biosimilars, dynamics in the TNF-α inhibi-
tors class could be reinvestigated. In addition, the entry of 
oncology biosimilars provides a new opportunity to gain 
knowledge on how biosimilars are implemented into clinical 
practice under different disease conditions.
5  Conclusion
By revisiting the history of infliximab and etanercept bio-
similar adoption in healthcare regions in England, Scotland 
and Wales, we identified factors characterizing early and late 
adopters. The main driver for all regions to use biosimilars 
was the savings potential. Regions with a proactive attitude, 
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good stakeholder relationships leading to gain share agree-
ments, and clinician engagement were identified as early 
adopters.
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